company logo

Director, Government Pricing & Reporting in Cambridge, MA

Save

compensation:

$250K - $500K*

specialty:

Corporate Finance, Life Sciences, Risk & Quantitative Analysis

experience:

15+ years

Job Description

The Director, Government Pricing, Reporting, & Compliance leads Alnylam's Government Pricing "Group Practice" activities across several Expertise Areas, including Public Policy, Legal, Commercial and Finance. The role champions efforts that span a wide range of government pricing responsibilities, such as leading all aspects of government pricing – the data collection, calculations and verification for submission, the analysis of GP impacts on our business, as well as strategic and operational assessments of channel and commercial strategies. This role requires both technical analysis, leadership skill and an outstanding ability to communicate with colleagues across functions.


Summary of Key Responsibilities

  • Serve as Alnylam's primary subject matter expert on government pricing, reporting, and state price reporting matters.
  • Serve as the knowledge and process leader working with Finance, Commercial, and Legal regarding the col
See More

Valid through: 2020-4-9

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. In 2002, Alnylam was founded by Phillip Sharp, Paul Schimmel, David Bartel, Thomas Tuschl, John Kennedy Clarke, and Phillip Zamore, and John Maraganore was named CEO. The company was named after Alnilam, a star in Orion’s belt. The spelling was modified to make it unique. In 2003, Alnylam merged with the German pharmaceutical company, Ribopharma AG. The newly formed company also received $24.6 million in funding from private-equity firms. On February 27, 2004, Alnylam Pharmaceuticals filed for an IPO. The company raised $26 million and began trading as ALNY on the Nasdaq stock exchange. In 2005, the company partnered with Medtronic to develop drug-device combinations to treat neurodegenerative disorders. Alnylam partnered with Biogen Idec to discover and develop potential treatments of progressive multifocal leukoencephalopathy in 2006. In July 2007, Alnylam entered into a nonexclusive alliance with the Swiss drug company, Hoffmann-La Roche, in which Alnylam received $331 million upfront in exchange for access to its technology platform. In September 2007, Alnylam partnered with Isis Pharmaceuticals to found the company Regulus Therapeutics, a company focused on discovery, development, and commercialization of microRNA therapeutics.
Total Jobs:
20
Total Experts:
4
Average Pay:
$138,968
Total value of jobs:
$8,755,000
% Masters:
52%
Learn More About Alnylam Pharmaceuticals
* Ladders Estimates

More Jobs at Alnylam Pharmaceuticals

Similar Jobs

More Pharmaceuticals & Biotech Jobs

DATA SCIENTIST

$90K - $120K

Yesterday

Find similar Government Relations Communication Manager jobs: